TGF-β1 regulation of multidrug resistance pglycoprotein in the developing male blood-brain barrier

Endocrinology

Volumn 155, Issue 2, 2014, Pages 475-484

  Baello, Stephanie ^a   Iqbal, Majid ^a   Bloise, Enrrico ^a   Javam, Mohsen ^a   Gibb, William ^b   Matthews, Stephen G ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b Faculty of Medicine   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; BONE MORPHOGENETIC PROTEIN 9; DORSOMORPHIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CELL; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOTHELIUM CELL; EXPERIMENTAL GUINEA PIG; FEMALE; FETUS DEVELOPMENT; INFANT; MALE; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PERINATAL DEVELOPMENT; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GUINEA PIGS; MALE; P-GLYCOPROTEIN; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84893206590     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1472     Document Type: Article

References (55)

1. Mkresse S, Dehouck MP, Delorme P, et al. Bovine brain endothelial cells express tight junctions and monoamine oxidase activity in longterm culture. J Neurochem. 1989;53: 1363-1371.
2. Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA. 1989;86: 695-698.
3. Seetharaman S, Barrand MA, Maskell L, Scheper RJ. Multidrug resistance-related transport proteins in isolated human brain microvessels and in cells cultured from these isolates. J Neurochem. 1998;70: 1151-1159.
4. Saunders NR, Habgood MD, Dziegielewska KM. Barrier mechanisms in the brain, II. Immature brain. Clin Exp Pharmacol Physiol. 1999;26: 85-91.
5. Virgintino D, Errede M, Girolamo F, et al. Fetal blood-brain barrier P-glycoprotein contributes to brain protection during human development. J Neuropathol Exp Neurol. 2008;67: 50-61.
6. Zhou SF. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica. 2008;38: 802-832.
7. Petropoulos S, Gibb W, Matthews SG. Developmental expression of multidrug resistance phosphoglycoprotein (P-gp) in the mouse fetal brain and glucocorticoid regulation. Brain Res. 2010;1357: 9-18.
8. Ek CJ, Wong A, Liddelow SA, Johansson PA, Dziegielewska KM, Saunders NR. Efflux mechanisms at the developing brain barriers: ABC-transporters in the fetal and postnatal rat. Toxicol Lett. 2010; 197: 51-59.
9. Iqbal M, Gibb W, Matthews SG. Corticosteroid regulation of P-glycoprotein in the developing blood-brain barrier. Endocrinology. 2011;152: 1067-1079.
10. Dohgu S, Yamauchi A, Takata F, et al. Transforming growth factor-β1 upregulates the tight junction and P-glycoprotein of brain microvascular endothelial cells. Cell Mol Neurobiol. 2004;24: 491-497.
11. Sousa Vde O, Almeida JC, Eller CM, Gomes FC. Characterization of TGF-β1 type II receptor expression in cultured cortical astrocytes. In Vitro Cell Dev Biol Anim. 2006;42: 171-175.
12. de Sampaio e Spohr TC, Martinez R, da Silva EF, Neto VM, Gomes FC. Neuron-glia interaction effects on GFAP gene: a novel role for transforming growth factor-β1. Eur J Neurosci. 2002;16: 2059-2069.
13. Gomes FC, Sousa Vde O, Romão L. Emerging roles for TGF-β1 in nervous system development. Int J Dev Neurosci. 2005;23: 413-424.
14. Berezowski V, Landry C, Dehouck MP, Cecchelli R, Fenart L. Contribution of glial cells and pericytes to the mRNA profiles of P-glycoprotein and multidrug resistance-associated proteins in an in vitro model of the blood-brain barrier. Brain Res. 2004;1018: 1-9.
15. Boveri M, Berezowski V, Price A, et al. Induction of blood-brain barrier properties in cultured brain capillary endothelial cells: Comparison between primary glial cells and C6 cell line. Glia. 2005;51: 187-198.
16. Sobue K, Yamamoto N, Yoneda K, et al. Induction of blood-brain barrier properties in immortalized bovine brain endothelial cells by astrocytic factors. Neurosci Res. 1999;35: 155-164.
17. Tontsch U, Bauer H. Glial-cells and neurons induce blood-brain barrier related enzymes in cultured cerebral endothelial cells. Brain Res. 1991;539: 247-253.
18. Massagué J, Blain SW, Lo RS. TGFβ signaling in growth control, cancer, and heritable disorders. Cell. 2000;103: 295-309.
19. Goumans MJ, Valdimarsdottir G, Itoh S. Balancing the activation state of the endothelium via two distinct TGF-β type I receptors. EMBO J. 2002;21: 1743-1753.
20. Massagué J. TGF-β signal transduction. Annu Rev Biochem. 1998; 67: 753-791.
21. Shi Y, Massagué J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell. 2003;113: 685-700.
22. Goumans MJ, Valdimarsdottir G, Itoh S, et al. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFβ/ALK5 signaling. Mol Cell. 2003;12: 817-828.
23. ten Dijke P, Goumans MJ, Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis. 2008;11: 79-89.
24. Lebrin F, Mummery CL. Endoglin-mediated vascular remodeling: mechanisms underlying hereditary hemorrhagic telangiectasia. Trends Cardiovasc Med. 2008;18: 25-32.
25. Lastres P, Letamendíia A, Zhang H, et al. Endoglin modulates cellular responses to TGF-β 1. J Cell Biol. 1996;133: 1109-1121.
26. Kaname S, Ruoslahti E. Betaglycan has multiple binding sites for transforming growth factor-β 1. Biochem J. 1996;315: 815-820.
27. López-Casillas F, PayneHM,Andres JL, Massagué J. Betaglycan can act as a dual modulator of TGF-β access to signaling receptors: mapping of ligand binding and GAG attachment sites. J Cell Biol. 1994;124: 557-568.
28. Dean F, Matthews SG. Maternal dexamethasone treatment in late gestation alters glucocorticoid and mineralocorticoid receptor mRNA in the fetal guinea pig brain. Brain Res. 1999;846: 253-259.
29. Power LL, Popplewell EJ, Holloway JA, Diaper ND, Warner JO, Jones CA. Immunoregulatory molecules during pregnancy and at birth. J Reprod Immunol. 2002;56: 19-28.
30. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003;305: 197-204.
31. Inman GJ, Nicolás FJ, Callahan JF, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2002;62: 65-74.
32. Jinnin, M. Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-β1-induced extracellular matrix expression. Mol Pharmacoly. 2006;69: 597-607.
33. WuX,MaJ,HanJD,WangN, Chen YG. Distinct regulation of gene expression in human endothelial cells by TGF-β and its receptors. Microvasc Res. 2006;71: 12-19.
34. Larrivée B, Prahst C, Gordon E, et al. ALK1 signaling inhibits angiogenesis by cooperating with the Notch pathway. Dev Cell. 2012; 22: 489-500.
35. David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood. 2007;109: 1953-1961.
36. Hao J, Daleo MA, Murphy CK, et al. Dorsomorphin, a selective small molecule inhibitor of BMP signaling, promotes cardiomyogenesis in embryonic stem cells. PLoS One. 2008;63:e2904.
37. Dibrov A, Kashour T, Amara FM. The role of transforming growth factor β signaling in messenger RNA stability. Growth Factors. 2006;24: 1-11.
38. Diaz A, Chepenik KP, Korn JH, Reginato AM, Jimenez SA. Differential regulation of cyclooxygenases 1 and 2 by interlukin-1 β, tumornecrosis factor-α, and transforming growth factor-β 1 inhuman lung fibroblasts. Exp Cell Res. 1998;241: 222-229.
39. Sheng H, Shao J, Dixon DA, et al. Transforming growth factor-β1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intes tinal epithelial cells via stabilization of mRNA. J Biol Chem. 2000; 275: 6628-6635.
40. Patel VA, Dunn MJ, Sorokin A. Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J Biol Chem. 2002;277: 38915-38920.
41. Cordenonsi M, Montagner M, Adorno M, et al. Integration of TGF-β and Ras/MAPK signaling through p53 phosphorylation. Science. 2007;315: 840-843.
42. Olieslagers S, Pardali E, Tchaikovski V, ten Dijke P, Waltenberger J. TGF-β1/ALK5-induced monocyte migration involves PI3K and p38 pathways and is not negatively affected by diabetes mellitus. Cardiovasc Res. 2011;91: 510-518.
43. Lopez-Coviella I, Mellott TM, Kovacheva VP, et al. Developmental pattern of expression ofBMPreceptors and Smads and activation of Smad1 and Smad5 by BMP9 in mouse basal forebrain. Brain Res. 2006;1088: 49-56.
44. Chen GZ, Li TL, Quan W, et al. Expression of TGFβ1 and its type I receptors ALK1 and ALK5 mRNA in brain arteriovenous malformation. J S Med Univ. 2006;265: 675-677.
45. Vogelgesang S, Kunert-Keil C, Cascorbi I, et al. Expression of multidrug transporters in dysembryoplastic neuroepithelial tumors causing intractable epilepsy. Clin Neuropathol. 2004;235: 223-231.
46. Eickelberg O, Centrella M, Reiss M, Kashgarian M, Wells RG. Betaglycan inhibits TGF-β signaling by preventing type I-type II receptor complex formation. Glycosaminoglycan modifications alter betaglycan function. J Biol Chem. 2002;277: 823-829.
47. Wiater E, Vale W. Inhibin is an antagonist of bone morphogenetic protein signaling. J Biol Chem. 2003;278: 7934-7941.
48. Mallet C, Vittet D, Feige JJ, Bailly S. TGFβ1 induces vasculogenesis and inhibits angiogenic sprouting in an embryonic stem cell differentiation model: respective contribution of ALK1 and ALK5. Stem Cells. 2006;24: 2420-2427.
49. Dobbing J, Sands J. Growth and development of the brain and spinal cord of the guinea pig. Exp Neurol. 1970;28: 442-449.
50. Madazli R, Aydin S, Uludag S, Vildan O, Tolun N. Maternal plasma levels of cytokines in normal and preeclamptic pregnancies and their relationship with diastolic blood pressure and fibronectin levels. Acta Obstet Gynecol Scand. 2003;82: 797-802.
51. Enquobahrie DA, Williams MA, Qiu C, Woelk GB, Mahomed K. Maternal plasma transforming growth factor-β1 concentrations in preeclamptic and normotensive pregnant Zimbabwean women. J Matern Fetal Neonatal Med. 2005;17: 343-348.
52. Letterio JJ, Geiser AG, Kulkarni AB, Roche NS, Sporn MB, Roberts AB. Maternal rescue of transforming growth factor-β1 null mice. Science. 1994;264: 1936-1938.
53. Gressens P, Lammens M, Picard JJ, Evrard P. Ethanol-induced disturbances of gliogenesis and neuronogenesis in the developing murine brain: an in vitro and in vivo immunohistochemical and ultrastructural study. Alcohol Alcohol. 1992;27: 219-226.
54. McCaffery P, Deutsch CK. Macrocephaly and the control of brain growth in autistic disorders. Prog Neurobiol. 2005;77: 38-56.
55. Winship IR, Plaa N, Murphy TH. Rapid astrocyte calcium signals correlate with neuronal activity and onset of the hemodynamic response in vivo. J Neurosci. 2007;27: 6268-6272.